FDA delays PDUFA date for GSK's trametinib

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said FDA extended the PDUFA date by three months for an NDA for trametinib to treat patients with unresectable or metastatic melanoma with BRAF V600 mutations a...